This review provides a summary of presentations from the 2020 virtual European Hematology Association (EHA)-Scientific Working Group (SWG) Scientific Meeting on Immunotherapy for Hematological Disorders. The session focussed on the T-cell Ig and mucin domain containing protein-3 (TIM-3) receptor and its potential as a new target for drug development in the treatment of patients with higher-risk myelodysplastic syndrome (MDS).
EMJ Hematology 9 [Supplement 1] . 2021
April 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/07/Filgrastim-Prophylaxis-for-Neutropenia-in-Myelodysplasia-Pre-Surgery-Case-Report-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Diffuse-Large-B-Cell-Lymphoma-of-Spleen-A-Key-Differential-of-Nodular-Splenomegaly-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/The-Impact-of-‘Pre-conception-on-Conception-An-Inadvertent-Form-of-Infertility-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Hema_Article_Waheed-940x564.jpg)